What the published research actually shows
Advocacy without evidence is noise, so this page collects the peer-reviewed literature we rely on and is explicit about its limits. The most-cited work is the magnesium–ibogaine study in special-operations veterans with traumatic brain injury, published in Nature Medicine in 2024, alongside functional-neuroimaging work and reviews of psychedelics in TBI. These are small, mostly open-label studies with short follow-up — genuinely striking results that are not the same thing as proof of safety or efficacy for any individual. Below the published work we set out the three research programmes we believe Israel should run next: expanded controlled trials, neuroimaging and biomarkers, and long-term safety tracking.
Last reviewed:
Key Research: Ibogaine in Military Veterans
Magnesium–Ibogaine Therapy in Veterans with Traumatic Brain Injuries
Journal: Nature Medicine (2024)This landmark Stanford study investigated the magnesium-ibogaine (MISTIC) protocol in veterans with comorbid TBI and PTSD, providing crucial evidence for ibogaine's neurorestorative potential.
Neural Correlates of Ibogaine: Evidence from Functional Neuroimaging
Journal: Biological Psychiatry (2026)This Stanford fMRI study of 30 Special Operations veterans found ibogaine drives widespread brain reorganisation, correlating with improvements in TBI-related disability.
Psychedelics for the Management of Symptoms of Traumatic Brain Injury
Journal: PNPBP (2026)This open-access global survey study examined the use of psychedelics for managing TBI symptoms across a broad international population, providing real-world evidence.
Pioneering the Next Wave of Ibogaine Research
Building on initial successes, future research initiatives will broaden the scope of inquiry, refine treatment protocols, and deepen our understanding of ibogaine’s therapeutic mechanisms. This strategic expansion is vital for establishing ibogaine as a widely accepted neurorestorative therapy.
Expanded Clinical Trials
Beyond TBI and PTSD, studies will explore ibogaine’s efficacy in other neurological and psychiatric conditions, including severe depression, anxiety disorders, and neurodegenerative conditions, utilising larger, more diverse cohorts.
Neuroimaging & Biomarkers
Advanced fMRI, PET scans, and genetic sequencing will uncover the precise neural circuits and biological markers associated with ibogaine’s brain repair effects, paving the way for personalised medicine approaches.
Long-term Efficacy & Safety
Longitudinal studies tracking patients over several years will provide critical data on sustained therapeutic benefits, relapse prevention, and long-term safety profiles, addressing concerns for chronic conditions.
These studies will cement Israel’s role as a leader in psychedelic neuroscience, transforming treatment paradigms for a range of complex conditions.
Help make ibogaine therapy available in Israel
Add your name to the public petition, or contact us about research collaboration, clinical partnership, volunteering, or media enquiries. We reply to every message.